文献速递类风湿关节炎

基线PD-1+TFh与CTLA-4+CD4+ T细胞预测早期类风湿关节炎CTLA-4Ig治疗后的缓解

Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本研究纳入60例未经治疗的早期类风湿关节炎(eRA)患者,来自一项更大的随机试验,分别接受甲氨蝶呤联合CTLA-4Ig(阿巴西普,n=17)、抗IL-6受体(托珠单抗,n=21)或抗TNF(赛妥珠单抗聚乙二醇,n=22)治疗。主要结局为第24周CDAI缓解(CDAI≤2.8)。结果显示,在CTLA-4Ig治疗患者中,基线PD-1+TFh和CTLA-4+常规CD4+ T细胞比例可预测第24周CDAI缓解;而抗IL-6R或抗TNF治疗后的缓解无法由CD4+ T细胞亚群比例预测。

要点

  • 基线PD-1+TFh和CTLA-4+常规CD4+ T细胞比例可预测CTLA-4Ig治疗后第24周CDAI缓解。
  • CD4+ T细胞亚群比例不能预测抗IL-6R或抗TNF治疗后的缓解。
  • CTLA-4Ig显著降低Tregs和PD-1+TFh细胞比例,所有治疗组Tregs的CTLA-4表达均下降。

核心结论

  • 基线循环PD-1+TFh和CTLA-4+常规CD4+ T细胞比例可能作为早期RA经CTLA-4Ig治疗后缓解的预测生物标志物。

研究设计与样本

  • 研究纳入来自一项更大随机试验的60例未经治疗的早期RA患者,接受甲氨蝶呤联合CTLA-4Ig(n=17)、抗IL-6R(n=21)或抗TNF(n=22)治疗。
  • 通过流式细胞术检测基线及治疗第4、12、24周时12种CD4+ T细胞亚群比例,主要结局为第24周CDAI缓解(CDAI≤2.8)。

主要发现

  • 在CTLA-4Ig治疗患者中,基线PD-1+TFh和CTLA-4+常规CD4+ T细胞比例可预测第24周CDAI缓解。
  • CD4+ T细胞亚群比例不能预测抗IL-6R或抗TNF治疗后的缓解。
  • 所有治疗组第24周时表达CTLA-4的调节性T细胞(Tregs)百分比均下降,但仅CTLA-4Ig治疗显著降低Tregs和PD-1+TFh细胞比例。

关键数值与推荐

  • 主要结局为第24周CDAI缓解,定义为CDAI≤2.8。
  • 疾病活动度通过CDAI、DAS28、肿胀关节数、压痛关节数、CRP和ESR评估。

临床怎么用

  • 对于早期RA患者,基线PD-1+TFh和CTLA-4+常规CD4+ T细胞比例可能有助于预测CTLA-4Ig治疗后的缓解,指导治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Treatment with CTLA-4Ig blocks T-cell activation and is clinically effective in RA. However, it is unknown if specific CD4+ T-cell subsets in blood at baseline predict remission after CTLA-4Ig, or other biological treatments with different modes of action, and how treatment affects CD4+ T cells in patients with untreated early RA (eRA). METHODS: This study included 60 patients with untreated eRA from a larger randomized trial. They were treated with methotrexate combined with CTLA-4Ig (abatacept, n = 17), anti-IL6 receptor (tocilizumab, n = 21) or anti-TNF (certolizumab-pegol, n = 22). Disease activity was assessed by clinical disease activity index (CDAI), DAS28, swollen joint counts, tender joint counts, CRP and ESR. The primary outcome was CDAI remission (CDAI ≤ 2.8) at week 24. Proportions of 12 CD4+ T-cell subsets were measured by flow cytometry at baseline and after 4, 12 and 24 weeks of treatment. RESULTS: In patients treated with CTLA-4Ig, the proportions of PD-1+TFh and CTLA-4+ conventional CD4+ T cells at baseline predicted CDAI remission at week 24. CD4+ T-cell subset proportions could not predict remission after treatment with anti-IL6R or anti-TNF. The percentage of regulatory T cells (Tregs) expressing CTLA-4 decreased in all treatment arms by 24 weeks, but only CTLA-4Ig treatment significantly reduced the proportions of Tregs and PD-1+T follicular helper (TFh) cells. CONCLUSION: These findings indicate that circulating proportions PD-1+TFh and CTLA-4+ conventional CD4+ T cells at baseline may serve as predictive biomarkers for remission in early RA after CTLA-4Ig treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Aldridge J, Andersson K, Gjertsson I, et al. Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34009274. doi:10.1093/rheumatology/keab454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。